ETView Medical enters into patent license agreement for thoracic surgery devices

NewsGuard 100/100 Score

ETView Medical Ltd. (TASE: ETVW) announced today that it has entered into an exclusive license agreement for 2 US patents with James S. Simon, M.D., of Tiburon, California. The licensed patents are U.S. Pat. No. 7,052,456, entitled "Airway products having LEDs", and U.S. Pat. No. 6,189,533, entitled "Endotracheal Intubation Device". Both patents complement issued and pending US and international patents held by ETView covering the VivaSight™-SL Airway Management System.

“As an innovator in medical device technology, we recognize and respect the contribution of individual inventors such as Dr. Simon in the creation of new and important technologies. Our VivaSight™ airway management system provides best-in-class solutions for sophisticated thoracic surgical procedures requiring lung isolation.”

ETView's patented VivaSight-SL is a single-use disposable medical device, consisting of a single lumen ventilation tube with an integrated continuous high resolution video imaging system. VivaSight is currently sold in Europe, Israel, and the US. VivaSight overcomes current endotracheal tube intubation limitations and associated adverse surgical events during lung isolation surgeries. Lung isolation is employed to provide one-lung ventilation in patients undergoing thoracic, cardiac, vascular, or esophageal surgeries. During lung isolation, temporary visualization of the patient airway is achieved with a fiberoptic bronchoscope while the patient is ventilated and the target lung isolated. Intra-operative surgical maneuvers often require repeated imaging and partial blocking of the airway to maintain lung isolation. It is estimated that over 1.9 million lung isolation procedures are conducted worldwide annually, accounting for over $250mm in single-use medical disposables.

William Edelman, CEO of ETView Medical commented, "We are pleased to enter into a patent license agreement with Dr. Simon." Mr. Edelman continued, "As an innovator in medical device technology, we recognize and respect the contribution of individual inventors such as Dr. Simon in the creation of new and important technologies. Our VivaSight™ airway management system provides best-in-class solutions for sophisticated thoracic surgical procedures requiring lung isolation."

During February 2012, ETView announced distribution agreements with NeuroMed Ltd. (NeuroMed) a surgical products sales and distribution company based in St. Petersberg, Russia, and State of the Art (SOTA) Medical Products, Inc., a specialty surgical products sales and distribution company, based in Cedar Grove, New Jersey.

On December 12, 2011, ETView announced that the company has successfully completed filing of a Pre-Marketing Notification Application (510(k)) with the US Food and Drug Administration (FDA) for the VivaSight™-DL Airway Management System. VivaSight-DL is a proprietary, single-use disposable medical device, consisting of a dual lumen airway ventilation tube with an integrated continuous high resolution video airway imaging system permitting airway control and lung isolation during certain surgical procedures.

ETView has pioneered development of the VivaSight platform (previously known as TVT™), combining an airway ventilation tube with integrated continuous high resolution airway imaging for patient airway control and lung isolation capability (eliminating the need for fiberoptic bronchoscope imaging during these procedures).

Source ETView Medical Ltd.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
What does the future hold for obesity medication development?